COSCIENS Biopharma Inc T.CSCI

New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024Company ended the quarter with US$27.8 million in cashTORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI...read article.

[lscfa]

Cooked books.   Last year Aeterna reported Q2 revenue of $2.246M, now it shows it as $1.392M

[lscfa]

w-t-h?       Ceapro revenue Aeterna revenue Total  Cosciens Q2 24       2,337 Q1 24 2,774 4 2

[lscfa]

Adjusting for Fx and removing Aeterna license fees & development services....       Cdn   US US US US US   Ceapro revenue Avg fx rate for qtr

[lscfa]

Ceapro revs down vs q1 24. Gross profit impacted by merger?     Revenues Gross profit Gross margin Q2 24 2,334,000 819,000 35.1% Q1 24 2,773,788 1,218,406 43

[lscfa]

Ceapro revenues up from q1 24 after factoring in fx...     Cdn Cdn     Revenues Gross profit Gross margin Q2 24 3,194,312 1,120,883 35.1%

[lscfa]

Lousy disclosure. Cash flow from ops in qtr was $3.2M burn but the bozos did not say how much was due to one-time expenses for merger.

[prophetoffactz]

News release: Operating Expenses Our total operating expenses for the three-month period ended June 30, 2024, was $4.5 million as compared with $1.9 million for the same period in 2023. This increase of $2.6 million was due to higher research and development costs associated with the Avenanthramides and DETECT clinical trials of $0.8 million and selling, general and administrative costs of

[lscfa]

This means cosciens SG&A is higher due to merged SG&A of 2 co.s.  It does NOT mean it was a merger related expense.

[lscfa]

I think the one-time merger expenses were included in q1 SG&A for CZO and AEZS and the $3M US is the new recurring level of SG&A. Fire someone.         CZO  AEZS Total Q1 24      

[prophetoffactz]

The merger wasn't completed until Jun. 6 or basically the end of the quarter. The TSX-V listing expenses will fall off. Human resources can be streamlined. They only need one CFO for instance. There are fewer member of the Board of Directors to pay at the combined company. Some operations could be consolidated. The cost of the diagnostic trial is over and the diagnostic is set to become a